Company Overview of NovaDigm Therapeutics, Inc.
NovaDigm Therapeutics, Inc. develops vaccines to protect patients from fungal and bacterial infections. Its products include NDV-3, a vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by fungal and bacterial pathogens; and Als3, an antigen vaccine, which provides protection against systemic and mucosal candidal infections. NovaDigm Therapeutics, Inc. was founded in 2005 and is based in Grand Forks, North Dakota.
4201 James Ray Drive
REAC 1 Building
Grand Forks, ND 58202
Founded in 2005
Key Executives for NovaDigm Therapeutics, Inc.
NovaDigm Therapeutics, Inc. Key Developments
Similar Private Companies By Industry
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
|7 Oaks Pharmaceutical Corp.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|Citizens Budget Commission||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact NovaDigm Therapeutics, Inc., please visit www.novadigmtherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.